Microalbuminuria is an important biomarker for the development of diabetic nephropathy and cardiovascular complications. Since microalbuminuria is not easily detected on routine urinalysis, current guidelines recommend measuring spot urine albumin-to-creatinine ratio (uACR) annually in a patient with diabetes mellitus. While the standard method is quantitative measurement using turbidimetric immunoassay, it requires high cost and special laboratory equipment. This may be a hurdle that prevents screening for microalbuminuria in many patients with diabetes. Therefore, a semi-quantitative uACR test, which is rapid and inexpensive, could be used as a substitute to the current standard quantitative measurement. The investigators aimed to assess the diagnostic accuracy of a semi-quantitative urine albumin-to-creatinine ratio test, URiSCAN 2ACR, as a screening tool for microalbuminuria in patients with diabetes.
Study Type
OBSERVATIONAL
Enrollment
1,000
measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test
measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
Seoul National University Hospital
Seoul, South Korea
Diagnostic Sensitivity and Specificity
Diagnostic Sensitivity and Specificity of URiSCAN 2ACR compared with standard method
Time frame: through study completion, an average of 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.